Iovance Biotherapeutics Inc.
IOVA | NASDAQ
$10.19
-$0.06 (-0.59%)
At close: Sep 21, 2026, 4:00 PM ET
$10.25
+$0.06 (+0.59%)
Pre-market:
Sep 22, 2026, 9:15 AM ET
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 324.97M | 285.61M | 263.5M | 250.43M | 241.52M | 212.68M | 164.07M | 90.86M | 32.77M | 1.9M | 1.19M | 707K | 238K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | -52.97M | -41.44M | 7.29M | 153.36M | 191.77M | 166.48M | 124M | 82.82M | 47.33M | 18.02M | 10.76M | 6.39M | 2.05M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 377.94M | 327.04M | 256.22M | 97.07M | 49.75M | 46.2M | 40.07M | 8.04M | -14.56M | -16.11M | -9.57M | -5.68M | -1.81M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -301.31M | -363.18M | -403.36M | -416.47M | -410.64M | -398.78M | -395.28M | -429.96M | -459.25M | -467.43M | -460.56M | -446.34M | -428.37M | -418.02M | -398.88M | -391.31M | -377.15M | -358.85M | -342.7M | -311.77M | -284.5M | -266.7M |
Interest Income | 8.66M | 12.76M | 14.65M | 16.9M | 20.9M | 20.16M | 20.27M | 13.82M | 13.17M | 12.9M | 13.04M | 11.64M | 9.06M | 6.37M | 2.99M | 1.4M | 746K | 436K | 451K | 453K | 728K | 1.26M |
Pretax Income | -293.78M | -354.76M | -393.05M | -398.33M | -389.73M | -378.62M | -375.01M | -416.14M | -446.08M | -454.53M | -447.52M | -434.7M | -419.31M | -411.66M | -395.89M | -389.9M | -376.41M | -358.41M | -342.25M | -311.32M | -283.77M | -265.44M |
Net Income | -289.52M | -353.86M | -390.98M | -397.63M | -389.92M | -375.36M | -372.18M | -410M | -440.22M | -449.64M | -444.04M | -432.98M | -418.84M | -411.66M | -395.89M | -389.9M | -376.41M | -358.41M | -342.25M | -311.32M | -283.77M | -265.44M |
Selling & General & Admin | 109.65M | 147.35M | 152.32M | 158.68M | 163.68M | 160.17M | 142.37M | 129.77M | 117.18M | 104.91M | 106.92M | 103.48M | 104.41M | 108.81M | 104.1M | 101.48M | 94.48M | 87.46M | 83.66M | 75.9M | 70.93M | 65.97M |
Research & Development | 270.44M | 285.88M | 300.27M | 303.64M | 296.71M | 279.43M | 282.34M | 297.58M | 316.86M | 341.13M | 344.08M | 337.18M | 322.16M | 309.22M | 294.78M | 289.82M | 282.68M | 271.39M | 259.04M | 235.87M | 213.57M | 200.72M |
Other Expenses | 299.16M | 257M | 206.98M | 51.22M | -1K | 5.38M | 10.65M | 10.65M | 10.65M | 5.27M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 679.25M | 690.22M | 659.57M | 513.54M | 460.39M | 444.98M | 435.35M | 438M | 444.69M | 451.31M | 450.99M | 440.66M | 426.56M | 418.02M | 398.88M | 391.31M | 377.15M | 358.85M | 342.7M | 311.77M | 284.5M | 266.7M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | 33.35M | 33.35M | 33.35M | 33.35M | 17.86M | 17.86M | 17.86M | 17.86M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 626.28M | 648.79M | 666.86M | 666.9M | 652.16M | 611.46M | 559.35M | 520.82M | 492.03M | 469.33M | 461.75M | 447.05M | 428.61M | 418.02M | 398.88M | 391.31M | 377.15M | 358.85M | 342.7M | 311.77M | 284.5M | 266.7M |
Income Tax Expense | -4.26M | -898K | -2.07M | -697K | 188K | -3.26M | -2.83M | -6.15M | -5.87M | -4.89M | -3.48M | -1.72M | -477K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 450.19M | 418.51M | 406.97M | 364.04M | 334.51M | 322.87M | 304.89M | 303.27M | 284.82M | 266.22M | 255.95M | 245.82M | 224.48M | 213.69M | 164.77M | 157.82M | 157.27M | 157.11M | 156.92M | 155.51M | 153.75M | 147.37M |
Shares Outstanding (Diluted) | 450.19M | 418.51M | 406.97M | 364.04M | 334.51M | 322.87M | 304.89M | 303.27M | 284.82M | 266.22M | 255.95M | 245.82M | 224.48M | 213.69M | 164.77M | 157.82M | 157.27M | 157.11M | 156.92M | 155.51M | 153.75M | 147.37M |
EPS (Basic) | -0.70 | -0.92 | -1.09 | -1.20 | -1.23 | -1.24 | -1.30 | -1.49 | -1.67 | -1.80 | -1.88 | -2.05 | -2.22 | -2.38 | -2.46 | -2.47 | -2.39 | -2.29 | -2.22 | -2.06 | -1.91 | -1.85 |
EPS (Diluted) | -0.70 | -0.92 | -1.09 | -1.20 | -1.23 | -1.24 | -1.30 | -1.49 | -1.67 | -1.80 | -1.88 | -2.05 | -2.22 | -2.38 | -2.46 | -2.47 | -2.39 | -2.29 | -2.22 | -2.06 | -1.91 | -1.85 |
EBITDA | -262.8M | -321.35M | -357.11M | -354.63M | -347.9M | -337.86M | -335.41M | -378.52M | -405.72M | -417.19M | -414.39M | -405.58M | -394.87M | -389.8M | -374.76M | -362.26M | -350M | -334.48M | -320.64M | -301.74M | -278.24M | -263.04M |
EBIT | -293.78M | -354.76M | -393.05M | -398.33M | -393.74M | -382.63M | -379.01M | -420.15M | -446.08M | -454.53M | -447.52M | -434.7M | -419.31M | -411.66M | -395.89M | -389.9M | -376.41M | -358.41M | -342.37M | -311.58M | -284.42M | -266.7M |
Depreciation & Amortization | 30.98M | 33.41M | 35.94M | 43.7M | 45.84M | 44.76M | 43.61M | 41.63M | 40.36M | 37.34M | 33.13M | 29.12M | 24.45M | 21.85M | 21.14M | 27.64M | 26.41M | 23.93M | 21.73M | 9.84M | 6.18M | 3.66M |
Add to Watchlist
Select watchlists to add or remove IOVA